Nurexone Biologic Inc (NRX.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 13 | 15 | 3 | 18 | 6 |
| Accounts receivable | -3 | -185 | -79 | 33 | 131 |
| Other Working Capital | 122 | -582 | -99 | 239 | -38 |
| Other Operating Activity | -1,002 | -713 | -458 | -1,079 | -795 |
| Operating Cash Flow | $-870 | $-1,465 | $-633 | $-789 | $-696 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -61 | -241 | -67 | 1 | -2 |
| Other Investing Activity | -10 | 0 | 23 | 0 | 0 |
| Investing Cash Flow | $-71 | $-241 | $-44 | $1 | $-2 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -7 | -8 | -8 | -11 | -1 |
| Common Stock Issued | 0 | 566 | 3 | 737 | 0 |
| Other Financing Activity | 51 | 3,840 | 95 | 325 | 0 |
| Financing Cash Flow | $44 | $4,398 | $90 | $1,051 | $-1 |
| Exchange Rate Effect | 27 | 22 | -15 | 0 | -9 |
| Beginning Cash Position | 3,255 | 541 | 1,143 | 880 | 1,588 |
| End Cash Position | 2,385 | 3,255 | 541 | 1,143 | 880 |
| Net Cash Flow | $-897 | $2,692 | $-587 | $263 | $-699 |
| Free Cash Flow | |||||
| Operating Cash Flow | -870 | -1,465 | -633 | -789 | -696 |
| Capital Expenditure | -61 | -241 | -67 | N/A | -2 |
| Free Cash Flow | -931 | -1,706 | -700 | -789 | -698 |